Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 306

1.

Prognostic value of C-reactive protein as an inflammatory and N-terminal probrain natriuretic peptide as a neurohumoral marker in acute heart failure (from the Korean Heart Failure registry).

Park JJ, Choi DJ, Yoon CH, Oh IY, Jeon ES, Kim JJ, Cho MC, Chae SC, Ryu KH, Yoo BS, Kang SM, Oh BH; KorHF Registry.

Am J Cardiol. 2014 Feb 1;113(3):511-7. doi: 10.1016/j.amjcard.2013.10.022. Epub 2013 Nov 9.

PMID:
24315115
2.

Incremental value of high-sensitivity C-reactive protein and N-terminal pro-B-type natriuretic peptide for the prediction of postoperative cardiac events in noncardiac vascular surgery patients.

Goei D, Hoeks SE, Boersma E, Winkel TA, Dunkelgrun M, Flu WJ, Schouten O, Bax JJ, Poldermans D.

Coron Artery Dis. 2009 May;20(3):219-24. doi: 10.1097/MCA.0b013e3283219e47.

PMID:
19322079
3.
4.

Combined use of high-sensitivity cardiac troponin T and N-terminal pro-B type natriuretic peptide improves measurements of performance over established mortality risk factors in chronic heart failure.

de Antonio M, Lupon J, Galan A, Vila J, Urrutia A, Bayes-Genis A.

Am Heart J. 2012 May;163(5):821-8. doi: 10.1016/j.ahj.2012.03.004.

PMID:
22607860
5.

N-terminal probrain natriuretic peptide and C-reactive protein in stable coronary heart disease.

Ndrepepa G, Kastrati A, Braun S, Mehilli J, Niemöller K, von Beckerath N, von Beckerath O, Vogt W, Schömig A.

Am J Med. 2006 Apr;119(4):355.e1-8.

PMID:
16564781
6.

Incremental prognostic power of novel biomarkers (growth-differentiation factor-15, high-sensitivity C-reactive protein, galectin-3, and high-sensitivity troponin-T) in patients with advanced chronic heart failure.

Lok DJ, Klip IT, Lok SI, Bruggink-André de la Porte PW, Badings E, van Wijngaarden J, Voors AA, de Boer RA, van Veldhuisen DJ, van der Meer P.

Am J Cardiol. 2013 Sep 15;112(6):831-7. doi: 10.1016/j.amjcard.2013.05.013. Epub 2013 Jun 29.

PMID:
23820571
7.

High-sensitivity C-reactive protein and N-terminal pro-B-type natriuretic peptide in patients with stable coronary artery disease: a prognostic study within the CLARICOR trial.

Harutyunyan MJ, Mathiasen AB, Winkel P, Gøtze JP, Hansen JF, Hildebrandt P, Jensen GB, Hilden J, Jespersen CM, Kjøller E, Kolmos HJ, Gluud C, Kastrup J; CLARICOR Trial Group.

Scand J Clin Lab Invest. 2011 Feb;71(1):52-62. doi: 10.3109/00365513.2010.538081. Epub 2010 Nov 25.

PMID:
21108561
8.

Probrain natriuretic peptide and C-reactive protein as markers of acute rejection, allograft vasculopathy, and mortality in heart transplantation.

Arora S, Gullestad L, Wergeland R, Simonsen S, Holm T, Hognestad A, Ueland T, Geiran O, Andreassen A.

Transplantation. 2007 May 27;83(10):1308-15.

PMID:
17519779
9.

Incremental prognostic value of C-reactive protein and N-terminal proB-type natriuretic peptide in acute coronary syndrome.

Kim H, Yang DH, Park Y, Han J, Lee H, Kang H, Park HS, Cho Y, Chae SC, Jun JE, Park WH.

Circ J. 2006 Nov;70(11):1379-84.

10.

Clinical utility of N-terminal pro-B-type natriuretic peptide for risk stratification of patients with acute decompensated heart failure. Derivation and validation of the ADHF/NT-proBNP risk score.

Scrutinio D, Ammirati E, Guida P, Passantino A, Raimondo R, Guida V, Sarzi Braga S, Pedretti RF, Lagioia R, Frigerio M, Catanzaro R, Oliva F.

Int J Cardiol. 2013 Oct 3;168(3):2120-6. doi: 10.1016/j.ijcard.2013.01.005. Epub 2013 Feb 6.

PMID:
23395457
11.

Lack of decrease in plasma N-terminal pro-brain natriuretic peptide identifies acute heart failure patients with very poor outcome.

Kubler P, Jankowska EA, Majda J, Reczuch K, Banasiak W, Ponikowski P.

Int J Cardiol. 2008 Oct 13;129(3):373-8. Epub 2007 Dec 4.

PMID:
18054808
12.

[Comparative prognostic value of plasma and urinary N-terminal pro-B-type natriuretic peptide in patients with acute destabilized heart failure].

Manzano-Fernández S, Januzzi JL, Boronat García M, Bonaque-González JC, Muñoz-Esparza C, Albaladejo-Otón MD, Pastor-Pérez FJ, Pastor P, Valdés M, Pascual-Figal DA.

Rev Esp Cardiol. 2011 May;64(5):365-72. doi: 10.1016/j.recesp.2010.10.017. Epub 2011 Mar 11. Spanish.

13.

Risk stratification with the use of serial N-terminal pro-B-type natriuretic peptide measurements during admission and early after discharge in heart failure patients: post hoc analysis of the PRIMA study.

Eurlings LW, Sanders-van Wijk S, van Kraaij DJ, van Kimmenade R, Meeder JG, Kamp O, van Dieijen-Visser MP, Tijssen JG, Brunner-La Rocca HP, Pinto YM.

J Card Fail. 2014 Dec;20(12):881-90. doi: 10.1016/j.cardfail.2014.08.014. Epub 2014 Aug 28.

14.

Combination of uric acid and NT-ProBNP: a more useful prognostic marker for short-term clinical outcomes in patients with acute heart failure.

Park HS, Kim H, Sohn JH, Shin HW, Cho YK, Yoon HJ, Nam CW, Hur SH, Kim YN, Kim KB, Park HJ.

Korean J Intern Med. 2010 Sep;25(3):253-9. doi: 10.3904/kjim.2010.25.3.253. Epub 2010 Aug 31.

15.

Acute changes in N-terminal pro-B-type natriuretic peptide during hospitalization and risk of readmission and mortality in patients with heart failure.

Michtalik HJ, Yeh HC, Campbell CY, Haq N, Park H, Clarke W, Brotman DJ.

Am J Cardiol. 2011 Apr 15;107(8):1191-5. doi: 10.1016/j.amjcard.2010.12.018. Epub 2011 Feb 4.

PMID:
21296322
16.

Risk stratification in stable coronary artery disease: superiority of N-terminal pro B-type natriuretic peptide over high-sensitivity C-reactive protein, gamma-glutamyl transferase, and traditional risk factors.

Bode E, Wuppinger T, Bode T, Alber H, Ulmer H, Pachinger O, Mair J.

Coron Artery Dis. 2012 Mar;23(2):91-7. doi: 10.1097/MCA.0b013e32834f1165.

PMID:
22157356
17.

Comparison of midregional pro-atrial natriuretic peptide with N-terminal pro-B-type natriuretic peptide in predicting survival in patients with chronic heart failure.

von Haehling S, Jankowska EA, Morgenthaler NG, Vassanelli C, Zanolla L, Rozentryt P, Filippatos GS, Doehner W, Koehler F, Papassotiriou J, Kremastinos DT, Banasiak W, Struck J, Ponikowski P, Bergmann A, Anker SD.

J Am Coll Cardiol. 2007 Nov 13;50(20):1973-80. Epub 2007 Oct 29.

18.

A prospective cohort study of prognostic power of N-terminal probrain natriuretic peptide in patients with non-ST segment elevation acute coronary syndromes.

Ndrepepa G, Braun S, Mehilli J, Niemöller K, Schömig A, Kastrati A.

Clin Res Cardiol. 2007 Jan;96(1):30-7. Epub 2006 Oct 30.

PMID:
17066344
19.
20.

Usefulness of a combination of monocyte chemoattractant protein-1, galectin-3, and N-terminal probrain natriuretic peptide to predict cardiovascular events in patients with coronary artery disease.

Tuñón J, Blanco-Colio L, Cristóbal C, Tarín N, Higueras J, Huelmos A, Alonso J, Egido J, Asensio D, Lorenzo Ó, Mahíllo-Fernández I, Rodríguez-Artalejo F, Farré J, Martín-Ventura JL, López-Bescós L.

Am J Cardiol. 2014 Feb 1;113(3):434-40. doi: 10.1016/j.amjcard.2013.10.012. Epub 2013 Nov 7.

PMID:
24295549

Supplemental Content

Support Center